Learn more about whether Exact Sciences Corporation or Insmed Incorporated is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Exact Sciences Corporation’s EXAS share price has surged by 5.01%, which has investors questioning if this is right time to sell.

What Happened? Shares of diagnostic company Exact Sciences Corporation (NASDAQ:EXAS) jumped 15.2% in the morning session ...

U.S. stocks were higher, with the Dow Jones index gaining around 400 points on Friday. Shares of Trupanion, Inc. TRUP +18.4% ...

Exact Sciences posted better-than-expected Q1 results and lifted its 2025 outlook, signaling confidence in growth and ...

Exact Sciences reports strong Q1 2025 results with 11% revenue growth, boosted by Cologuard Plus and Oncodetect.

Diagnostic company Exact Sciences Corporation (NASDAQ:EXAS) in Q1 CY2025, with sales up 10.9% year on year to $706.8 million.

Exact Sciences (NASDAQ:EXAS) shares surge as strong demand for diagnostic tests boosts revenue guidance despite an earnings ...

Following the launch of two new cancer tests—plus a third planned for before the end of 2025—Exact Sciences is nudging up its ...

The company best known for its Cologuard colon cancer screening test posted a loss of $101.2 million, or $0.54 per share, on ...

Exact Sciences Corp. (EXAS) on Thursday reported a loss of $101.2 million in its first quarter. On a per-share basis, the ...